FDA Alerts
Hepatitis C and HIV Drug Interactions
The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals and patients that drug interactions between the hepatitis C virus ( HCV ) protease inhibitor Victrelis ( boceprevir ) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors ( atazanavir , lopinavir , darunavir ) can potentially reduce the effectiveness of these medicines when they are used together.
FDA Hepatitis Update - Pegasys and Copegus
On August 22, 2011, the FDA approved the combination of Pegasys and Copegus for the treatment of chronic hepatitis C virus ( HCV ) infection in pediatric patients 5 through 17 years of age.